Abstract Transgenic mice overexpressing human APOE*3-Leiden are highly susceptible to diet-induced hyperlipoprotein emia and atherosclerosis due to a defect in hepatic uptake of remnant lipoproteins. In addition to the human APOE*3Leiden gene, these mice carry the human APOC1 gene (APOE*3Leiden-Cl). To investigate the possible effect of simultaneous expression of the human APOC1 gene, we examined the phenotypic expres sion in these A POE* 3 Leiden-C l mice in relation to trans genic mice expressing the A PO i^Leiden gene without the APOC1 gene (APOE*3Leiden-HCR). APO£*3Leiden-Ci and APO^SLeiden-HCR mice had comparable liver expression for the AP0.E*3Leiden transgene and high total cholesterol levels on a sucrose-based diet compared with control mice (4.3 and 4.3 versus 2.1 mmol/L). In addition, on this diet APOE*3L&iden-C 1 mice displayed significantly higher serum triglyceride levels than APOE*3Leiden-HCR mice and control mice (4.4 versus 0.6 and 0.2 mmol/L). Elevated triglyceride and cholesterol levels were mainly in the VLDL-sized lipoproteins. In vivo turnover studies with endogenously triglyceride-labeled VLDL showed a reduced
VLDL triglyceride fractional catabolic rate for AP0£*3Leiden-C1 and APÒ-È^ Leiden-HCR mice compared with control mice (3.5 and 11.0 versus 20.4 pools per hour). To study whether the difference in fractional catabolic rates between the two transgenic strains was due to an inhibiting effect of apoCl on the extrahe patic lipolysis or hepatic-mediated uptake of VLDL, turnover ex periments were performed in functionally hepatectomized mice. Strikingly, both APOE*3h&iàe,x\-Cl and APOE*3Leiden-HCR mice showed a decreased lipolytic rate of VLDL triglyceride in the extrahepatic circulation compared with control mice (1.5 and 1.8 versus 6.3 pools per hour). We conclude that next to an im paired hepatic uptake, overexpression of the APOiE^Leiden gene influences the extrahepatic lipolysis of VLDL triglycerides, whereas simultaneous overexpression of the APOC1 gene leads to a further decrease in hepatic clearance of VLDL. n humans carrying the APOE*3Leiden gene, the ac cumulation of chylomicron and VLDL rem nant li poproteins in the circulation is inherited in a dom i nant fashion. 1 The underlying mechanism is assumed to be a defect of this variant in binding to the hepatic lipo protein receptors. 2 We have studied3,4 the effect o f the apoE*3Leiden protein in lipoprotein metabolism in more detail by using transgenic mice expressing the hum an APOE*3Leiden gene. The high-expressing A P O E * 3-Leiden transgenic mouse lines accumulate rem nant li poproteins in the plasm a and develop atherosclerotic lesions, especially after consuming fat-and cholesterol-containing diets. As expected, in vivo V LD LapoB turnover studies show that the hypercholesterol emia in these mice is indeed due to a defect in hepatic uptake of rem nant lipoproteins. 5 Since at the time of the generation of these mice the exact location of the HCR of the APOE gene was un known, except that it lies about 9 kb downstream of the APOC1 gene, 6 we used a 27-kb DNA construct covering the APOE*3Leiden and APO C1 genes and the HCR el ement. Western blot analysis showed that these APOE*3-Leiden transgenic mice express both genes (designated A PO -E^Leiden-Ci transgenics) . 3 Thus, we cannot ex clude that the hyperlipidemia and atherosclerosis ob served in these transgenic mice is (partly) due to the coexpression of the human APOC1 gene.
Little is known about the in vivo function of the apoCl protein, although in vitro studies have shown that apoCl can inhibit the LPL-mediated hydrolysis of VLDL TGs. 7, 8 Studies involving the addition o f purified human apoCl to chylomicrons9 and TG em ulsions10 show inhibition of their uptake by perfused rat livers. Furthermore, apoCl prevents apoE-mediated VLDL binding to the LDL re ceptor11 and the LDL receptor-related protein in vi tro, 12, 13 presumably by displacing apoE from the VLDL particle. 14 The observation that transgenic mice with high liverspecific expression of the human APOC1 gene exhibit hypertriglyceridemia15 suggests that a direct inhibiting ef fect of apoC 1 on either apoE-mediated remnant clearance or VLDL TG lipolysis holds true for the in vivo situation as well. However, such a role for apoCl could not be deduced from the results we obtained with A p o C l-defi-Selected Abbreviations and Acronyms FCR = fractional catabolic rate FF A = free fatty acid HCR = hepatic control region HFC = high fat/high cholesterol Km = Michaelis-Menten constant LFC = low fat/low cholesterol LPL = lipoprotein lipase LR = lipolytic rate PAGE = polyacrylamide gel electrophoresis SDS = sodium dodecyl sulfate SR = secretion rate SRM-A = standard rat mouse TG = triglyceride Vmax ~ maximal enzyme activity cient m ice. 16 Although a lower level of plasm a lipids was expected in these mice, w e observed that m ice with total apoC 1 deficiency have normal plasma cholesterol levels on a regular chow diet, whereas after a severely hypercholesterolemic diet, A p o C l-deficient mice exhibit mildly elevated plasma cholesterol levels. Thus, the exact role apoCl plays in rem nant lipoprotein metabolism in vivo cannot be deduced from these studies with genetically modified mice.
In the present article we report on our study o f the effect of APOC1 gene coexpression on the phenotype o f APOE* 3-Leiden transgenic mice by comparing the APOE*3Leiden-C1 mice described above with transgenic mice carrying only the AEPOE*3Leiden gene directly linked to the HCR ele ment, thus without coexpressing the APOC1 gene (desig nated APOis^Leiden-HCR transgenics). By performing in vivo turnover studies with autologous TG-labeled VLDL samples, we found that additional apoCl protein indeed in hibits the hepatic uptake of remnant lipoproteins in vivo, whereas apoCl does not inhibit VLDL TG lipolysis. More strikingly, besides an inhibitory effect on hepatic uptake, we found that enrichment of VLDL particles with the apoE*3-Leiden protein also resulted in a disturbed extrahepatic lipolysis of VLDL TGs.
Methods

DNA Construct
The APO¿¿*3Leiden-HCR construct was generated from plas mid pJS276 (kindly provided by Dr J.D. Smith, Rockefeller Uni versity, New York, NY), which carries both the APOE*3 gene (from the -650-bp Bgl II site to the 1.9-kb //indili site) and a 5.5-kb BamHl fragment from the 5' region of APOC1', including the HCR. 17 The APOE* 3Leiden gene was introduced into pJS276 by exchanging a 2-kb EcöRI fragment encompassing exon 4 of the APOE*3 gene with the similar fragment from a cosmid car rying APOE*3Leiden. The resulting insert (APOE* 3Leiden-HCR) was excised from the plasmid by using the restriction en zymes Kpn I and HinäSl.
Generation and Analysis of Transgenic Mice
APO£*3Leiden-Ci mice were generated previously. 3, 4 Trans genic and nontransgenic littermates were obtained by breeding with C57BL/6J mice. Mice of the F7 generation were used for the present experiments. APOE* 3Leiden-HCR mice were generated according to the method of Hogan et al18 with some minor modifications. In brief, a DNA solution was microinjected into male pronuclei of fertil ized mouse eggs taken from superovulated FI (C57BL/6J*CBA/ J) females. Transgenic offspring were identified by polymerase chain reaction analysis and Southern blot analysis on genomic tail-derived DNA.3 Six founders were obtained from which one line with high liver expression of the APOE*3Leiden transgene was bred with C57BL/6J mice. Mice of the F4 generation were used for the experiments.
All mice in this study were females housed under standard conditions with free access to water and food. Nontransgenic littermates were used as a control group. All experiments were performed at 1 p m with food withdrawn at 9 a m .
Northern Blot Analysis
Transgenic mice were anesthetized with an intraperitoneal in jection of 0.5 mL/kg Hypnorm (Janssen Pharmaceutical) and 12.5 mg/kg midazolam (Roche Netherlands bv), and the livers were excised for quantification of APOE* 3 Leiden and APOC I mRNA. Total RNA was isolated from liver by using the RNAZOL pro cedure (Cinna/Biotecx). RNA samples (7.5 j à g per lane) were separated by electrophoresis through a denaturing agarose gel (1% wt/vol) containing 7.5% formaldehyde and were transferred to a nylon membrane (Hybond N, Amersham) according to the manufacturer's recommendations. Blots were subsequently hy bridized with 32P-labeled probes of human APOE cDNA, human APOC1 cDNA, 19 mouse ApoCl cDNA, 20 and a rat GAPDH cDNA21 in a solution containing 50% formamide. The intensity of the hybridization signal was quantified by using a Phosphor Imager (Molecular Dynamics). The amounts of APOE*3Leiden and APOC1 mRNA were related to the level of GAPDH mRNA.
Diets and Dietary Treatment
After weaning at 28 days of age, mice were fed an SRM-A (chow) diet. After 7 weeks of age, two different diets (Hope Farms) were administered to groups of each strain (at least eight mice per group). These diets were semisynthetic and composed essentially according to Nishina et al. 22 First, mice were fed an LFC diet containing 50.5% sucrose, 12.2% com starch, 5% com oil, and 5% cellulose (by weight) 4 for 3 weeks. Thereafter, the same mice were fed an HFC diet for 3 weeks containing 15% cocoa butter, 0.25% cholesterol, and 40.5% sucrose (by weight) . 23 After each dietary treatment, 100 (iL whole blood was obtained from each fasting mouse via tail bleeding. For fast protein liquid chromatography fractionation of lipo proteins, 2 0 0 /iL pooled serum from at least eight fasted mice per group was injected onto a 25-mL Superose 6 preparation-grade column (Pharmacia) and eluted at a constant flow rate of 0.5 mL/ min with phosphate-buffered saline, pH 7.4. Fractions of 0.5 mL were collected and assayed for cholesterol and TG levels as de scribed above.
Analysis of Lipids and Lipoproteins
Protein concentrations in lipoprotein fractions were determined by using the method of Lowry et al24 with bovine serum albumin as a standard.
VLDL fractions (¿<1.006 g/mL) were isolated from the pooled serum of at least 1 0 mice by ultracentrifugation at 40 0 0 0 rpm in an SW-40 swingout rotor (Beckman) for 18 hours at 5°C.
Quantification of Human ApoE
Serum human apoE*3Leiden concentrations were measured by using a sandwich enzyme-linked immunosorbent assay.4 Affin ity-purified polyclonal goat anti-human apoE antibodies were used for coating, and polyclonal rabbit anti-human apoE was used as the secondary antibody. After incubation of the plates with swine anti-rabbit IgG antibodies conjugated to horseradish per oxidase, detection was done by the immunoperoxidase procedure using tetramethylbenzidine as substrate. Pooled plasma from healthy human subjects with known apoE levels was used as a standard. 
SDS-PAGE and W estern Blot Analysis
From each lipoprotein fraction, 1.5-fj.g protein samples were analyzed for apolipoproteins by using SDS-PAGE with 4% to 2 0 % gradient gels. Proteins were either stained with Serva blue R or transferred to nitrocellulose membranes (Schleicher and Schuell) followed by incubation with polyclonal rabbit antisera against mouse apoCl or apoE and human apoCl or apoE. Goat anti-rabbit IgG conjugated to peroxidase (Nordic Immunology) was used as the secondary antibody, and detection was done by using the immunoperoxidase procedure with 4-chloro-1 -naphthol as substrate.
P rep aratio n of Endogenously Labeled VLDL
Fasted mice were anesthetized with 0.5 mL/kg IP hypnorm (Janssen Pharmaceutica) and 12.5 mg/kg IP midazolam (Roche). Body temperature was maintained with the use of heat lamps.
[3H]palmi tate dissolved in ethanol (Amersham) was evaporated under nitrogen and redissolved in 0.9% NaCl containing 2 mg/ mL bovine serum albumin. Mice were injected intravenously via the tail vein with 100 ¿¿Ci of the prepared [3H]paImitate. To de termine the efficiency of the in vivo [3H]palmitate incorporation into VLDL TGs, 50-fj.L blood samples were drawn at 2, 10, 20, 30, and 60 minutes after the [3H]palmitate injection. Lipids were extracted from the serum according to the method of Bligh and Dyer,25 and the amount of radioactivity in the TG fraction was determined after separation of the TGs from the other lipid com ponents by using thin-layer chromatography on silica gel 60 plates (Merck) with hexane/diethylether/acetic acid (83:16:1, voi/ vol/vol) as resolving solution. [,4C]tripalmitate (Amersham) was used as an internal standard, and the proportion of the radioac tivity in the plasma TG fraction was calculated in relation to the body mass of the mice. 26 To obtain VLDL radiolabeled in its TG moiety, anesthetized mice were injected as described above and bled from the retro-orbital plexus 25 minutes after injection. Ra diolabeled VLDL (d< 1.006 g/mL) used for clearance studies was isolated from the serum of six mice per group by using ultracen trifugation. These VLDL samples were dialyzed against phos phate-buffered saline, pH 7.4, at 4°C and subjected to lipid ex traction and thin-layer chromatography analysis. In all the VLDL fractions used, >95% of the radioactive label was bound to TGs.
In Vivo T urnover Studies Using [3H ]TG -Labeled VLDL
Whole Animal
To study the in vivo clearance of labeled VLDL TGs due to both peripheral lipolysis and hepatic uptake of the remnant par ticle, fasted mice were anesthetized and injected intravenously with 80 000 dpm [3H]TG-labeled VLDL (autologous injections). The disappearance of the radiolabeled VLDL was determined from 40-juL blood samples drawn at times after the injection as indicated. Total plasma radioactivity was used to represent VLDL TG radioactivity, as a pilot study showed that the disappearance of radioactivity as measured after lipid extraction followed by thin-layer chromatography TG analysis did not differ from the disappearance of total plasma radioactivity (not shown). The ra dioactivity at each time point was multiplied by the plasma vol ume of the animal26 and divided by the injected dose. The data were modeled by a biexponential curve from which the FCR was calculated by using the reciprocal area under the curve. The SR was calculated by multiplying the FCR by the plasma VLDL TG pool size as measured in each mouse during the experiment.
Functionally Hepatectomized Animal
To investigate the in vivo clearance of radiolabeled VLDL due to peripheral lipolysis only, mice were functionally hepatecto mized to exclude hepatic VLDL TG production and uptake.27 Mice were anesthetized, and the hepatic portal vein and the he patic artery were ligated prior to injections. [•'HJTG-labeled VLDL was injected, and blood samples were drawn and analyzed as described above. The data were kinetically modeled to cal culate the LR by using the reciprocal area under the curve. To ensure total exclusion of the liver from the circulation, liver ra dioactivity was measured at the end of the experiment by using a sample oxidizer (Packard Instrument Co). For each hepatecto mized mouse used in this study <0.5% of the injected dose was found in the liver.
In Vivo Hepatic VLDL TG Production by T rito n WR1339 Injection Fasted mice were injected with Triton WR1339 (500 mg/kg body wt IV) by using a 15% (wt/vol) Triton solution in 0.9% NaCl. Plasma VLDL clearance is virtually completely inhibited under these circumstances.28 Blood samples were drawn at ap propriate times (up to 60 minutes) after the Triton WR1339 in jection. TGs were measured in the plasma and related to the body mass of the mice as described above. Production of hepatic TGs was calculated from the slope of the curve and expressed as milli moles per hour per kilogram body weight.
LPL-M ediated In V itro Lipolysis of VLDL
In vitro lipolysis assays with isolated VLDL fractions (d< 1.006 g/mL) were performed at 37°C in a 0.1-mol/L Tris buffer, pH 8.5, for 10 minutes with commercially available LPL (Sigma) in the presence of 2% (wt/vol) essentially FFA-free albumin. The reaction was stopped by adding stop buffer containing 50 mmol/ L KH2PO4 and 0.1% Triton X-100, pH 6.9, and placed on ice. To obtain a time zero control, the reaction was prevented by adding stop buffer prior to adding LPL and placed on ice. FF As were measured as described above. The rate of FFA release by LPL was linear for the 10 minutes used in this assay. The assay was performed on five different VLDL concentrations (<¿<1.006 g/mL) in the range of 0.05 to 0.5 mmol/L with duplication of FFA determination. Apparent Km and Vm ax of VLDL as substrate for LPL were calculated from Lineweaver-Burk plots.
Results
C haracterization of A P O i^L e id e n -H C R and AP02£*3Leiden-C/ Mice Six founder mice carrying the APOB^Leiden-HCR construct (Fig 1 ) were generated. Two strains showed high-level expression in the liver. For the present study one of these strains was further characterized that showed hepatic A P O i^L eid en mRNA levels comparable with the previously generateci APOE*3\-,&iden-Cl mice of line 2 ( Table 1 ). In addition, APOE*3Leiden-C l mice also ex hibited hepatic expression of human APOC1 mRNA, 3 whereas the hepatic mouse A poC l mRNA levels of APOE*3Leiden-HCR and AP0£*3Leiden-C7 mice did not differ from that of control mice (99 ±25% and 109±26% of control value).
Human apoE*3Leiden levels, as quantified in individual mouse serum, were significantly elevated in APOE*3Lei-den-Cy mice compared with A P O i^L eid en -H C R mice ( Table 1 ). The two transgenic mouse strains were further characterized by analyzing the apolipoprotein composition of VLDL fractions (¿<1.006 g/mL). SDS-PAGE and Western blot analysis showed that both strains had equal amounts of human apoE*3Leiden protein on VLDL (Fig  2 a) . The amount of mouse apoE on VLDL was similar in both APO E*3Leiden-HCR and APOE*3heiden~Cl mice compared with control mice (Fig 2b) . As expected, human apoCl was found only onAPOE*3Leiden~Cl VLDL (Fig  2c) . Furthermore, mouse apoCl (showing cross-reactivity with mouse apoC3) did not differ between APOE*3Lei-den-HCR, APOE*3Leide,n-Cl, and control mice (Fig 2d) . Serva blue R staining showed that the total amount of apoE was increased «tw ofold in both AP(?£'*3Leiden-HCR and APOE*3L,&id&n-C 1 mice compared with control mice (Fig  2e) . Analysis of the lipid composition of APOE*3Leiden-HCR and APOE*3Leiden-CJ VLDL revealed no differ ences (not shown).
Serum lipids were measured in fasting transgenic mice and nontransgenic littermates as control animals. When kept on an SRM-A chow diet, both APOE*3L&iden-Cl and A PO E^Leiden-H C R mice showed significantly ele vated levels of serum cholesterol compared with control mice. Furthermore, serum TG levels were significantly el evated, being most pronounced in APOE*3Leiden-Cl mice (Table 1 ) .
Feeding sucrose is known to stimulate hepatic VLDL TG production. 22 To investigate the response of both trans genic mouse lines to a sucrose-rich diet, mice were fed an LFC diet containing 50.5% sucrose. After 3 weeks on the LFC diet, the total serum cholesterol levels of both APOE*3L,eiden-Cl and APOAE^Leiden-HCR mice were elevated compared with their respective levels on the SRM-A diet and significantly different from control mice. In addition, upon sucrose feeding the serum TG level fur ther increased in APOE*3Leid&n-Cl mice, whereas, re markably, it remained unaltered in APOE* 3 Lei den-HCR mice (Table 1 ). This increase in serum TGs for APO£*3Leiden-C7 mice was confined to the VLDL-sized Western blot analyses of mouse lipoproteins. VLDL (d< 1.006 g/mL) was isolated by ultracentrifugation from the pooled serum of 9 control (lane 1), 9 /4PO£*3Lelden-HCR (lane 2), and 9 APO£*3Leiden-C7 (lane 3) fasted mice. VLDL protein (7.5 //g) was subjected to SDS-PAGE (4% to 20% gradient gels) and transferred to a nitrocellulose membrane. The membrane was incubated with polyclonal antisera against human apoE (a), mouse apoE (b), human apoCl (c), or mouse apoCl (d). Total apoE was stained with Serva blue R (e). Note the double band In d, which is due to cross-reactivity of the mouse apoCl anti serum with mouse apoC3.
fractions as determined by fast protein liquid-Superose 6 chromatography (not shown). W e also compared both transgenic lines and control mice regarding their response to cholesterol feeding. After 3 weeks on the HFC diet (0.25% cholesterol), total serum cholesterol levels were increased among all groups com pared with the LFC and SRM-A diets but were more pro nounced in the transgenic mice. Serum TG levels in the APOE*3Leiden-Cl mice were lower on the HFC diet than on the SRM-A and LFC diets.4 TG levels in A PO ü^L eiden-H C R and control mice remained un changed upon cholesterol feeding (Table 1) .
TG Turnover Studies in AP0Z?*3Leiden Transgenic and Control Mice
To investigate the mechanisms underlying the pronounced hypertriglyceridemia in APOE* 3 Leiden-C1 mice relative to APOZr^SLeiden-HCR and control mice, we performed VLDL TG turnover studies. Prior to these experiments, all mice were fed for 3 weeks with the sucrose-containing LFC diet because the hypertriglyceridemia of AP02iif!3Leiden-C/ mice was most pronounced when fed this diet. APOE*3Leiden-C l, APO£*3Leiden-HCR, and control mice were injected with [3H]palmitate, and the appearance of label in plasma TGs was followed over time. Almost all the [3H]palmitate (99.4%) was cleared from the plasma for all groups 2 minutes after injection (results not shown). The initial rate of appearance in the plasma of 3H-labeled TGs was similar for both transgenic and control mice (Fig 3) . However, the larger area under the curve suggests that clear ance from the plasma was delayed in APOE*3Leiden-Cl mice compared with APOE* 3Leiden-HCR and control mice.
Endogenously labeled VLDL (d< 1.006 g/mL) was iso lated from serum collected from mice 25 minutes after [3H]palmitate injection. After autologous injection, the la beled VLDL TGs were cleared at a reduced rate in APOE*3L&id&n-Cl mice compared with AP0.E*3Leiden-HCR and control mice (34% versus 14% and 7% of the injected dose was still present in the plasma 12.5 minutes after injection; Fig 4) . From these data the FCRs and SRs FCRs were calculated from in vivo clearance studies of labeled autol ogous VLDL in transgenic and control mice (Fig 4) , From these date SRs were calculated by multiplying the FCR by the pool size. LRs were cal culated from the in vivo clearance of labeled VLDL in hepatectomlzed transgenic and control mice (Fig 5) . Values are mean±SD (n«7 mice/ group). *P < .05 control vs transgenic mice; tP<«05 APOE*SLQ\ä&r\«C1 (E*3L-C1) vs /\POP3Leiden-HCR (E"3L-HCR) by nonparametrlc MannWhitney U test. «m were calculated (Table 2 ). In A P OE* 3 Lei de n-C l and APOE*3Leiden-HCR mice the VLDL FCRs were signif icantly decreased compared w ith that in control mice (3.5 and 11.0 versus 20.4 pools p e r hour).
VLDL SRs were significantly elevated APOE*3Leiden-Ci and A P0£*3L eiden-H C R mice com pared with control mice (Table 2 ). Direct assessm ent o f the in vivo VLDL TG production rate by injecting Triton WR1339 gave similar results (0.23±0.10, 0.17± 0.07, and 0.14±0.08 mmol ■ h " 1 • kg ' 1 for A P O E^L eid en -H C R , APOE*3Leiden-C l , and control mice, respectively). These differences in V LD L production rate were not highly significant and can only partly explain the strongly decreased FCRs observed in both transgenic m ouse lines.
The VLDL TG FCR in AP<9£*3Leiden-C7 mice was much lower than that in AP<9£*3Leiden-HCR mice (3.5 versus 1 1 . 0 pools per hour). A disturbed extrahepatic LPLmediated lipolysis in the AP<9£*3Leiden-C/ mice could explain this difference. To test this hypothesis, control and transgenic mice were functionally hepatectomized to rule out VLDL TG clearance via the liver lipoprotein receptors. The rate of clearance from the extrahepatic circulation of [3H]TG-labeled autologous V LD L was ham pered in both transgenic lines compared w ith control mice (Fig 5) , By calculating the LR from these experiments, we could ob serve no significant difference between the two transgenic Mice fed the LFC diet for 3 weeks were functionally he patectomized, and 80 000 dpm in vivo labeled autologous VLDL was injected. The disappearance of the labeled VLDL was fo l lowed by counting the plasma radioactivity expressed as the percentage of the injected dose. Values are mean±SD for seven mice per group. Curves were calculated from the mean data by using a biexponential curve fit model. max mouse strains. However, the LRs of both APO-Z^Leiden-HCR and APOE*3Leiden-Cl mice were significantly lower than that of control mice (1.8 and 1.5 versus 6.3 pools per hour; Table 2 ). These results indicate that the presence of human apoE*3Leiden on the VLDL particle inhibits the lipolysis of VLDL TGs in the extrahepatic circulation in vivo. How ever, this is not true for in vitro lipolysis. Lineweaver-Burk plot analysis with VLDL samples (d < 1.006 g/mL) iso lated by ultracentrifugation from pooled serum from APOE*3Leiden-C l , APOE*3Leiden-HCR, and control mice revealed no differences among the different VLDL samples in suitability as substrate for LPL in vitro. No significant differences could be observed between the re spective VLDL samples in both the apparent Km and V values ( Table 3) .
Discussion
From our previous findings with AP0I?*3Leiden trans genic mice we cannot definitely conclude that the observed hyperlipidemia and atherosclerosis in these mice is due exclusively to the expression of the APOE*3Leiden gene, since these mice also express the human APOC1 gene. In vitro studies suggest that the function of the apoCl protein is related to LPL-mediated lipolysis in the extrahepatic circulation.7,8 However, apoCl may also inhibit the receptor-mediated uptake of VLDL remnants by the liver. 9"13 The recent finding that APOC1 transgenic mice display hypertriglyceridemia15 sustains these in vitro data but does not discriminate between the suggested functions for apoC 1, since in these studies in vivo VLDL TG or VLDL apoB turnover studies were not performed.
We generated A p o C l-deficient mice to clarify the in vivo role of apoC l. 16 However, the data obtained with these mice did not accord with an inhibitory effect of apoCl on VLDL catabolism. Although lower plasma lipid levels were expected in A p o C l-deficient mice, no overt effect of apoCl deficiency on plasma lipid levels could be observed. We reasoned that the low plasma lipid levels usually found in normal mice, which are due to a highly efficient lipoprotein metabolism, are already too low to be further decreased. We therefore decided to study the role of apoCl under conditions of hyperlipidemia in the APOE*3Leid&n mice by comparing the formerly described APOE*3Leiden-Cl mice with transgenic mice carrying only the APO.£*3Leiden gene directly linked to the HCR element. The generation of the APOE* 3Leiden-HCR DNA construct was made possible by the recent isolation of the HCR element by Shachter et al. 17 To discriminate between an effect of apoCl on either extrahepatic lipolysis or he patic uptake of VLDL, we performed in vivo turnover studies using autologous TG-labeled VLDL samples.
In both APO£*3Leiden-Ci and APO£* 3Leiden-HCR transgenics the FCR was significantly lower than in the control animals. For both transgenic lines the lower FCR can only partly be explained by a slightly increased VLDL production rate (Table 2) . It is obvious from these VLDL turnover studies that the actions of apoE* 3 Leiden and apoCl in inhibiting the overall in vivo VLDL TG clear ance rate are additive. By performing turnover studies in functionally hepatectomized animals we were able to show that overexpression of the APOC1 gene in addition to the APOZs* 3 Leiden gene indeed leads to a further inhibition of the hepatic uptake of remnant lipoproteins, since apoCl does not affect in vivo lipolysis. Values for apparent kinetic parameters for serum VLDL preparations (c/<1.006 g/mL) of /*POF3Leiden-C7 (E*3L-C1), /\POP3L8iden-HCR (E*3L-HCR), and control mice were calculated from Lineweaver-Burk plots and are mean±SD of four independent experiments per VLDL sample.
In vitro experiments9-11 suggest that the inhibitory effect of apoC 1 on the hepatic uptake of VLDL remnants is in dependent of the amount of apoE present on the particle but possibly due to an effect of apoC 1 on the conformation of apoE. Other studies suggest that apoCl displaces apoE from the particle, thereby decreasing the affinity of the particle for the receptor. 12' 14 From our results a displace ment of apoE by apoC 1 is not likely to occur (Fig 2) .
We have recently generated transgenic mice overexpress ing the human APOC1 gene only. Preliminary results show that the FI generation of these APOC1 mice are also hypertriglyceridemic due to a decreased VLDL TG FCR, whereas the in vivo lipolysis and production rate are not affected (unpublished results). Thus, these results support our conclusion that overexpression of APOC1 rather than in vivo lipolysis inhibits hepatic uptake of VLDL remnants.
Transgenic mice overexpressing the human APOC2 or APOC3 gene are also hypertriglyceridemie.28,29 In APOC3 transgenic mice the accumulation of VLDL TGs may be due mainly to a decreased ratio of apoE/apoC3 on the VLDL particle, leading to a decreased apoE-mediated he patic uptake of VLDL. In APOC2 transgenic mice the rel ative amount of apoE on the VLDL particle is also de creased. As VLDL from these APOC2 transgenic mice is less efficient in binding to heparin-Sepharose, it has been suggested that in APOC2 transgenic mice VLDL particles are less accessible to cell surface-bound LPL, thus leading to an inefficient in vivo lipolysis. 30 In addition to an inhibiting effect of apoCl on the he patic uptake of VLDL remnants, we also conclude from our results that enrichment of VLDL particles with the apoE*3Leiden protein results in a disturbed in vivo lipol ysis of VLDL TGs. ApoE has an inhibitory effect on the LPL catalytic activity. 31 Furthermore, a synthetic peptide (residues 139 through 153) corresponding to the receptorbinding domain of apoE also inhibits LPL activity. 32 Al though apoE*3Leiden differs from apoE by an additional repeat of residues 1 2 0 through 126,3 it might still show the inhibitory action similar to that described for the syn thetic peptide with residues 139 through 153.
Another explanation for the inhibiting of apoE*3Leiden on in vivo lipolysis might be that apoE*3Leiden containing /3-VLDL displays decreased binding affinity to heparan sulfate proteoglycans. 33 A de creased interaction of apoE*3Leiden VLDL with the ex tracellular matrix of endothelial cells would imply a de creased accessibility of apoE*3Leiden VLDL to the LPL enzyme residing on this matrix, thus resulting in a dis turbed in vivo lipolysis of apoE*3Leiden VLDL TGs.
The finding that both isolated apoE*3Leiden VLDLs are strongly enriched in apoE protein but do not differ from control VLDL in apparent Km value for in vitro LPL lipol ysis (using LPL in solution; Table 3 ) strongly tugues for the Arteriosclerosis, Thrombosis, and Vascular Biology V o i 16, N o 8 A u g u s t 1 9 9 6 inability of apoE*3Leiden to bind to proteoglycans as the direct cause for the inhibiting effect of the excess of this protein on in vivo lipolysis. These results also indicate that future studies concerning the suitability of VLDL samples as substrate for LPL should be performed in a system in which the LPL enzyme is immobilized on, eg, a heparinSepharose column as described by Clark and Quarfordt. 34 This will resemble the in vivo situation of VLDL TG li polysis much more than the system that is reported in Table  3 . Experiments with immobilized LPL are currently being performed with the present VLDL samples.
In conclusion, we showed that excess apoCl on the VLDL particle in vivo leads to a further impaired hepatic uptake of these particles from the circulation of APOE*3heid&n-Cl transgenic mice. In addition, an excess of apoE*3Leiden but not apoCl on the VLDL particle hampers the in vivo lipolysis of VLDL TGs. Thus, the absolute and relative amounts of both apoE and apoCl on VLDL particles might be strong factors for the underlying metabolic defect in hypertriglyceridemia.
